HomeCompareETRXF vs ABBV

ETRXF vs ABBV: Dividend Comparison 2026

ETRXF yields 1955.83% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETRXF wins by $8074278749.21M in total portfolio value
10 years
ETRXF
ETRXF
● Live price
1955.83%
Share price
$0.00
Annual div
$0.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8074278749.31M
Annual income
$7,336,393,929,103,473.00
Full ETRXF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ETRXF vs ABBV

📍 ETRXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETRXFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETRXF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETRXF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETRXF
Annual income on $10K today (after 15% tax)
$166,245.83/yr
After 10yr DRIP, annual income (after tax)
$6,235,934,839,737,952.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ETRXF beats the other by $6,235,934,839,716,896.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETRXF + ABBV for your $10,000?

ETRXF: 50%ABBV: 50%
100% ABBV50/50100% ETRXF
Portfolio after 10yr
$4037139374.71M
Annual income
$3,668,196,964,564,122.50/yr
Blended yield
90.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ETRXF
No analyst data
Altman Z
-4.4
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETRXF buys
0
ABBV buys
0
No recent congressional trades found for ETRXF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETRXFABBV
Forward yield1955.83%3.06%
Annual dividend / share$0.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8074278749.31M$102.3K
Annual income after 10y$7,336,393,929,103,473.00$24,771.77
Total dividends collected$8021814772.89M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ETRXF vs ABBV ($10,000, DRIP)

YearETRXF PortfolioETRXF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$206,283$195,583.33$11,550$430.00+$194.7KETRXF
2$3,991,338$3,770,615.13$13,472$627.96+$3.98METRXF
3$72,454,787$68,184,055.33$15,906$926.08+$72.44METRXF
4$1,234,298,166$1,156,771,543.45$19,071$1,382.55+$1234.28METRXF
5$19,737,611,186$18,416,912,148.66$23,302$2,095.81+$19737.59METRXF
6$296,356,706,041$275,237,462,071.92$29,150$3,237.93+$296356.68METRXF
7$4,179,383,287,333$3,862,281,611,869.30$37,536$5,121.41+$4179383.25METRXF
8$55,376,607,196,239$50,904,667,078,792.65$50,079$8,338.38+$55376607.15METRXF
9$689,611,981,503,379$630,359,011,803,402.50$69,753$14,065.80+$689611981.43METRXF
10$8,074,278,749,312,087$7,336,393,929,103,473.00$102,337$24,771.77+$8074278749.21METRXF

ETRXF vs ABBV: Complete Analysis 2026

ETRXFStock

Etrion Corporation does not have significant business operations. Previously, the company operated as an independent renewable energy developer in Japan. The company was formerly known as PetroFalcon Corporation and changed its name to Etrion Corporation in September 2009. Etrion Corporation was incorporated in 1993 and is based in Geneva, Switzerland.

Full ETRXF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ETRXF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETRXF vs SCHDETRXF vs JEPIETRXF vs OETRXF vs KOETRXF vs MAINETRXF vs JNJETRXF vs MRKETRXF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.